2025 Free Cash Flow Guidance: About $900 million, with cash conversion at about 95%. Equifax Inc (NYSE:EFX) achieved a strong financial performance in 2024, with revenue up almost 8% and adjusted ...

In a report released yesterday, Jason Haas CFA from Wells Fargo maintained a Buy rating on Equifax (EFX – Research Report), with a price target of $313.00. The company’s shares closed ...

In trading on Thursday, shares of Equifax Inc (Symbol: EFX) crossed below their 200 day moving average of $263.93, changing hands as low as $251.60 per share. Equifax Inc shares are currently ...

ATLANTA, Feb. 5, 2025 /PRNewswire/ -- Equifax® (NYSE: EFX) today announced that the Equifax Board of Directors declared a quarterly dividend of $0.39 per share, payable on March 14, 2025, to ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/equifax-board-of-directors-declares-quarterly-dividend-302369176.html SOURCE ...

Below is Validea's guru fundamental report for EQUIFAX INC (EFX). Of the 22 guru strategies we follow, EFX rates highest using our P/B Growth Investor model based on the published strategy of ...

In this article, I noted that the company did well when it reported results from its 96-week phase 2b HARMONY study using its drug Efruxifermin [EFX] for pre-cirrhotic Metabolic dysfunction ...

Among patients with baseline and week 96 biopsies (n=134), 39% of patients treated with 50mg EFX (n=46) experienced reversal of cirrhosis with no worsening of MASH, representing a 24% effect size ...